Crystal Shereen Denlinger

机构：Fox Chase Cancer Center, National Comprehensive Cancer Network · ORCID：0000-0002-5663-7751

发表论文 231 篇 · 总被引 12601 次 · h-index 45

代表论文

• Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (2024 · Annals of Oncology · 被引 347)
• Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study (2021 · The Lancet Oncology · 被引 68)
• Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors (2021 · Investigational New Drugs · 被引 36)
• Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). (2023 · Journal of Clinical Oncology · 被引 35)
• Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study (2025 · The Lancet Oncology · 被引 33)
• A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors (2023 · Nature Communications · 被引 31)